XL281

Known as: RAF Kinase Inhibitor XL281 
An orally active, small molecule with potential antineoplastic activity. XL281 specifically inhibits RAF kinases, located downstream from RAS in the… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

2009-2015
012320092015

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2016
Review
2016
The Ras/Raf/MEK/ERK signaling pathway involves various kinases in which each kinase is associated with one another through… (More)
Is this relevant?
2015
2015
BACKGROUND The use of BRAF inhibitors may lead to the development of cutaneous toxicities such as rashes, photosensitivity… (More)
  • figure 1
  • table 1
  • table 2
  • table 3
  • table 4
Is this relevant?
2014
2014
Background XL281 is a potent and selective inhibitor of wild-type and mutant RAF kinases with anti-tumor activity in multiple… (More)
  • table 1
  • table 2
  • table 3
  • figure 1
  • figure 2
Is this relevant?
Review
2013
Review
2013
The B-Raf protein is a key signaling molecule in the mitogen activated protein kinase (MAPK) signaling pathway and has been… (More)
  • figure 1
  • figure 2
  • table 1
  • table 2
Is this relevant?
2009
2009
3513 Background: XL281 is a potent and selective inhibitor of wild type and mutant RAF kinases showing anti-tumor activity in… (More)
Is this relevant?
2009
2009
AVos Life sciences has analysed the revenue contribution of organically developed, licensed or co-developed, acquired and joint… (More)
  • figure 1
Is this relevant?
2009
2009
Bristol–Myers Squibb (BMS) and Exelixis have entered into an agreement to co-develop two kinase inhibitors for oncology… (More)
  • table 1
Is this relevant?